About us

History

　　Anhui Union Pharmaceutical Technology Co., Ltd. was founded in 2014, is a technological ≤pharmaceutical enterprise focusing on R&D innovation and development of t₩he whole industrial chain industry. The company developed more than← 200 compounds and was granted for more than 20 intellectual property rights authorization≥s and applied for national high-tech enterprises inπ 2022.

　　In order to better operate the big health industry, the company is based on R&D, indusβtry and market development, intensive optimization of internal resources, and overall planning of i÷nterests and operational efficiency. In September 2021, the holding subsidiary Anhui Union Biomedical Co., Ltd. wa☆s established to engage in the quality research of bulk d&rugs and the development of pharmaceutical products, and the research' and development of health products. In January 2021, Shanghai Union Biomedi∏cal Technology Co., Ltd. was changed to gather multiple forces, Build a platform integ±rating intelligent medical care, high-end biomedical research and developΩment, product sales and capital operation.

　　In 2022, it will be a pharmaceutical intermediate and C♠DMO industrialization production platform under preparation;

　　In 2022, it will be a small-scale production base for hig&h-end intermediates and characteristic APIs;

　　The company has rich experience in R&D and industrial transforαmation of small molecule nucleic acids and ribonucleotide compounds.

　　Commercialized projects: At present, the company focuses on the fields of psychotropic→ drugs, diabetes drugs, antipyretic and analgesic drugs, anti-cancer and anti-virus dru≥gs.

　　The company is building a small-scale production platform for inσtermediates, CDMO, advanced intermediates and char$acteristic APIs.

　　Dangerous unit reactions often involved include: Foucault reac÷tion, hydrogenation reaction, nitration reaction, sulfonation reaction, halogenation reaction, Grig§nard reaction, diazotization reaction, etc.